Daily Roundup

PME.ASX VMM.ASX C79.ASX CTQ.ASX CBL.ASX

Pro Medicus is building on its strong track record with clients. The medical imaging software company renewed a five-year contract worth A$16 million with The Ohio State University Wexner Medical Center, bringing its total contract renewals for the financial year to A$141 million. The deal covers Visage 7 Workflow and Visage 7 Cardiology Imaging, and operates on a transaction-based model that could deliver additional upside as the center expands its use of the platform.

Viridis Mining and Minerals has reached a significant milestone in developing its Colossus Rare Earth Project. The company executed its first major project delivery contract with Brazilian electricity distributor DME, securing dedicated power transmission infrastructure to connect the project to the grid. The agreement covers a 3.2-kilometer, 138kV transmission line valued at approximately BRL3.97 million, with grid capacity reserved from December 2027. The infrastructure is being built with capacity for future expansion up to 90MVA, positioning Viridis for growth beyond its initial Stage 1 operations. The fixed-price package removes cost escalation risk and keeps the company on track for first production in the first half of 2028.

Chrysos Corporation is accelerating its growth trajectory with a fresh financial boost. The company secured a $200 million debt facility from a consortium including ANZ, NAB, and Export Finance Australia, replacing its previous asset-based financing with more favorable terms, lower fees, and better covenants. The new facility supports production of 18 PhotonAssay units annually, with orders extending to 22 units. Strong market demand is evident in the 23 new lease agreements signed year-to-date, while the company continues to process over one million samples monthly as gold market conditions remain buoyant.

Control Bionics is hitting its stride commercially. The brain-computer interface company received a dedicated HCPCS code in the US for its NeuroNode technology, a major validation that opens doors to broader funding. New distribution partnerships with Tobii Dynavox and PRC-Saltillo are already generating funded sales, while trials with sports teams and rehabilitation centers across Australia, the US, and internationally are validating real-world applications. The company is also on track to integrate Apple's brain-computer interface technology by the third quarter of 2026.

Careteq simplified its balance sheet as strategic investor Antanas Guoga converted 355,678 convertible notes into 35.6 million ordinary shares at $0.01 per share. The move reflects Guoga's continued confidence in the healthtech company and clears the capital structure of convertible notes and drawn debt, allowing Careteq to focus on its HMR Referrals platform and broader AI-enabled health offerings.